Glycine and D-Cycloserine in Schizophrenia
Schizophrenia
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring Adult, Amino Acids, Cycloserine, Female, Glycine, Human, Male, N-Methylaspartate, Placebos, Schizophrenia, Amino Acids -- blood, Cycloserine -- *therapeutic use, Glycine -- *therapeutic use, Schizophrenia -- *drug therapy, Schizophrenia -- physiopathology
Eligibility Criteria
Inclusion Criteria: Diagnosis of Schizophrenia Score of 27 or greater on the Scale for the Assessment of Negative Symptoms (SANS) Treatment with stable dose of clozapine for at least 4 weeks Between 18 and 65 years old Exclusion Criteria: No other antipsychotic medications in oral for for at least 3 months or in depot form for 6 months Current major depressive episode Current substance abuse diagnosis
Sites / Locations
- Freedom Trail Clinic
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Placebo Comparator
Experimental
Glycine
Placebo
D-Cycloserine
The patients will undergo a 2 week single blind placebo lead in followed by an 8 week randomly assigned double blind treatment phase with 30 grams of glycine in 7 ounces of lemonade twice a day in addition to clozapine treatment.
The patients will undergo a 2 week single blind placebo lead in followed by an 8 week randomly assigned double blind treatment phase with 30 grams of placebo powder in 7 ounces of lemonade twice a day in addition to clozapine treatment.
The patients will undergo a 2 week single blind placebo lead in followed by an 8 week randomly assigned double blind treatment phase with D-cycloserine in addition to clozapine treatment.